Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Skin Cancers and Melanoma

The melanoma program comprises of a diverse group of clinical and laboratory scientists with one common goal: Advancement of the treatment of melanoma.

Clinical Trials for Skin Cancers and Melanoma

11 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCMEL09109

06/03/2010

Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

Basic Science

VICCMEL0287

05/06/2003

Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

Diagnostic

VICCMEL1372

11/24/2014

FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma

Other

VICCMEL12117

02/18/2013

A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy

Treatment

VICCMEL1486

05/01/2015

A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Uveal Melanoma

Treatment

VICCMEL14106

03/25/2015

A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma

Treatment

VICCMEL1471

02/04/2015

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

Treatment

VICCPHI13113

01/22/2015

A Multicenter Phase 1 Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors.

Treatment

VICCMEL1457

01/19/2015

A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations

Treatment

VICCMEL1213

01/16/2015

Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204) with or without Bevacizumab in Patients with Stage IV BRAFV600 Mutant Melanoma

Treatment

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers